Literature DB >> 10497157

Identification of the potassium channel opener site on sulfonylurea receptors.

I Uhde1, A Toman, I Gross, C Schwanstecher, M Schwanstecher.   

Abstract

Diversity of sulfonylurea receptor (SUR) subunits underlies tissue specific pharmacology of K(ATP) channels, which represent critical regulators of electrical activity in numerous cells. Notably, the neuronal/pancreatic beta-cell receptor, SUR1, imparts high sensitivity to hypoglycemic sulfonylureas (SUs; e.g. glibenclamide) and low to potassium channel openers (KCOs; e.g. P1075), whereas the opposite drug sensitivities are conferred by cardiovascular receptors, SUR2A and SUR2B. By exchanging domains between SUR1 and SUR2B, we identify two regions (KCO I: Thr(1059)-Leu(1087) and KCO II: Arg(1218)-Asn(1320); rat SUR2 numbering) within the second set of transmembrane domains (TMDII) as critical for KCO binding. Swapping both regions reconstitutes KCO affinities and sensitivities of the donor SUR isoform. High glibenclamide affinity of SUR1 is not reduced by transfer of KCO I plus II from SUR2B, demonstrating that high SU and KCO affinity can coexist in the same SUR molecule. Consistently, high SU affinity was imparted on SUR2B by substituting the region separating KCO I and II (Ile(1088)-Val(1217)) with the corresponding domain of SUR1. We infer the receptor sites for KCOs and SUs to be closely associated within a regulatory domain (Thr(1059)-Asn(1320)) in TMDII of SURs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497157     DOI: 10.1074/jbc.274.40.28079

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Synthesis and characterization of a novel tritiated KATP channel opener with a benzopyran structure.

Authors:  P W Manley; C Löffler-Walz; U Russ; A Hambrock; T Moenius; U Quast
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Molecular analysis of the subtype-selective inhibition of cloned KATP channels by PNU-37883A.

Authors:  H Kovalev; J M Quayle; T Kamishima; D Lodwick
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

Review 3.  Sulphonylurea action revisited: the post-cloning era.

Authors:  F M Gribble; F Reimann
Journal:  Diabetologia       Date:  2003-06-18       Impact factor: 10.122

Review 4.  Muscle KATP channels: recent insights to energy sensing and myoprotection.

Authors:  Thomas P Flagg; Decha Enkvetchakul; Joseph C Koster; Colin G Nichols
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

Review 5.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 6.  Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes.

Authors:  Michael J Riedel; Diana C Steckley; Peter E Light
Journal:  Hum Genet       Date:  2004-11-23       Impact factor: 4.132

Review 7.  K(ATP) channel therapeutics at the bedside.

Authors:  A Jahangir; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-07       Impact factor: 5.000

8.  The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2.

Authors:  Damian Stephan; Eva Stauss; Ulf Lange; Holger Felsch; Cornelia Löffler-Walz; Annette Hambrock; Ulrich Russ; Ulrich Quast
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 9.  Hyperinsulinism of infancy: towards an understanding of unregulated insulin release. European Network for Research into Hyperinsulinism in Infancy.

Authors:  R M Shepherd; K E Cosgrove; R E O'Brien; P D Barnes; C Ammälä; M J Dunne
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

10.  Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells.

Authors:  M Gopalakrishnan; E J Molinari; C C Shieh; L M Monteggia; J M Roch; K L Whiteaker; V E Scott; J P Sullivan; J D Brioni
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.